JP2017514850A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514850A5
JP2017514850A5 JP2016566238A JP2016566238A JP2017514850A5 JP 2017514850 A5 JP2017514850 A5 JP 2017514850A5 JP 2016566238 A JP2016566238 A JP 2016566238A JP 2016566238 A JP2016566238 A JP 2016566238A JP 2017514850 A5 JP2017514850 A5 JP 2017514850A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
htbz
isoquinolin
hours
pyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016566238A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514850A (ja
JP6635945B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/029519 external-priority patent/WO2015171802A1/en
Publication of JP2017514850A publication Critical patent/JP2017514850A/ja
Publication of JP2017514850A5 publication Critical patent/JP2017514850A5/ja
Application granted granted Critical
Publication of JP6635945B2 publication Critical patent/JP6635945B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016566238A 2014-05-06 2015-05-06 多動性運動障害を処置するためのｖｍａｔ２インヒビター Active JP6635945B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461989240P 2014-05-06 2014-05-06
US61/989,240 2014-05-06
PCT/US2015/029519 WO2015171802A1 (en) 2014-05-06 2015-05-06 Vmat2 inhibitors for the treatment of hyperkinetic movement disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019181949A Division JP2019218407A (ja) 2014-05-06 2019-10-02 多動性運動障害を処置するためのｖｍａｔ２インヒビター

Publications (3)

Publication Number Publication Date
JP2017514850A JP2017514850A (ja) 2017-06-08
JP2017514850A5 true JP2017514850A5 (enExample) 2018-06-14
JP6635945B2 JP6635945B2 (ja) 2020-01-29

Family

ID=53264772

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016566238A Active JP6635945B2 (ja) 2014-05-06 2015-05-06 多動性運動障害を処置するためのｖｍａｔ２インヒビター
JP2019181949A Withdrawn JP2019218407A (ja) 2014-05-06 2019-10-02 多動性運動障害を処置するためのｖｍａｔ２インヒビター
JP2021153918A Withdrawn JP2021191799A (ja) 2014-05-06 2021-09-22 多動性運動障害を処置するためのｖｍａｔ２インヒビター
JP2024122223A Pending JP2024153782A (ja) 2014-05-06 2024-07-29 多動性運動障害を処置するためのｖｍａｔ２インヒビター

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019181949A Withdrawn JP2019218407A (ja) 2014-05-06 2019-10-02 多動性運動障害を処置するためのｖｍａｔ２インヒビター
JP2021153918A Withdrawn JP2021191799A (ja) 2014-05-06 2021-09-22 多動性運動障害を処置するためのｖｍａｔ２インヒビター
JP2024122223A Pending JP2024153782A (ja) 2014-05-06 2024-07-29 多動性運動障害を処置するためのｖｍａｔ２インヒビター

Country Status (24)

Country Link
US (3) US20170071932A1 (enExample)
EP (3) EP3139925B1 (enExample)
JP (4) JP6635945B2 (enExample)
KR (5) KR20200133003A (enExample)
CN (3) CN106456629A (enExample)
AU (1) AU2015256012B2 (enExample)
CA (1) CA2947736C (enExample)
CY (1) CY1125058T1 (enExample)
DK (2) DK3139925T3 (enExample)
ES (2) ES2976207T3 (enExample)
FI (1) FI3936130T3 (enExample)
HR (2) HRP20220025T1 (enExample)
HU (2) HUE057839T2 (enExample)
IL (1) IL248745B (enExample)
LT (2) LT3139925T (enExample)
MX (1) MX387625B (enExample)
NZ (1) NZ725826A (enExample)
PL (2) PL3936130T3 (enExample)
PT (2) PT3936130T (enExample)
RS (2) RS65359B1 (enExample)
RU (1) RU2753740C2 (enExample)
SI (2) SI3139925T1 (enExample)
SM (2) SMT202200193T1 (enExample)
WO (1) WO2015171802A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2018000121A1 (en) 2015-10-30 2019-10-04 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof
LT3394057T (lt) 2015-12-23 2022-06-27 Neurocrine Biosciences, Inc. Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą)
US10442800B2 (en) 2016-06-29 2019-10-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of NBI-98854, preparation method and use thereof
TW202515564A (zh) * 2016-12-02 2025-04-16 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
WO2018130345A1 (en) 2017-01-10 2018-07-19 Sandoz Ag Crystalline valbenazine free base
WO2018140092A1 (en) 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors
JP2020508337A (ja) 2017-02-27 2020-03-19 サンド・アクチエンゲゼルシヤフト バルベナジン塩の結晶形態
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
EP3606529A1 (en) * 2017-04-01 2020-02-12 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine for use in the treatment a movement disorder
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705305D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
JP7250692B2 (ja) * 2017-04-01 2023-04-03 アデプティオ ファーマシューティカルズ リミテッド 運動障害の治療における使用のためのジヒドロテトラベナジン
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
US20190111035A1 (en) * 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
WO2018200605A1 (en) * 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
US20200276184A1 (en) 2017-09-21 2020-09-03 Neurocrine Biosciences, Inc. High Dosage Valbenazine Formulation and Compositions, Methods, and Kits Related Thereto
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
EA202090932A1 (ru) 2017-10-10 2021-05-20 Нейрокрин Байосайенсиз, Инк Способы введения некоторых vmat2-ингибиторов
JP2021503009A (ja) * 2017-11-08 2021-02-04 フォアシー ファーマシューティカルズ シーオー．，リミテッド ジヒドロテトラベナジンのエステル
CN110621674B (zh) 2017-12-26 2022-03-29 苏州科睿思制药有限公司 一种Valbenazine二对甲苯磺酸盐的晶型及其制备方法和用途
DK3784237T3 (da) * 2018-04-25 2024-01-08 Shinkei Therapeutics Inc Indretning til transdermal levering af tetrabenazin
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
AU2019287524A1 (en) 2018-06-14 2020-12-24 Neurocrine Biosciences, Inc. VMAT2 inhibitor compounds, compositions, and methods relating thereto
JP2021528481A (ja) 2018-08-15 2021-10-21 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２阻害剤を投与するための方法
EP3860599B1 (en) 2018-10-04 2024-05-15 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
JOP20210274A1 (ar) * 2019-05-09 2023-01-30 Neurocrine Biosciences Inc طرق لإعطاء مثبط vmat2 معين
US10940141B1 (en) * 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2081929B1 (en) * 2006-11-08 2013-01-09 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
JP2010509336A (ja) * 2006-11-09 2010-03-25 ニューヨーク ユニバーシティ サンドイッチ材料の製造方法、ガラス／セラミック／ガラス複合構造物、ガラス／セラミック／ガラス、医科あるいは歯科補綴、およびガラス／ジルコニア／ガラスサンドイッチ材料
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
SI3061760T1 (en) 2008-09-18 2018-04-30 Auspex Pharmaceuticals, Inc. Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2
JP2013501810A (ja) * 2009-08-12 2013-01-17 ヴァリーント インターナショナル（バルバドス）エスアールエル 医薬組成物
EP2576552A4 (en) * 2010-06-01 2013-11-13 Aupex Pharmaceutical Inc BENZOQUINOLONE INHIBITORS OF VMAT2
EP4345100A3 (en) * 2012-09-18 2024-04-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
JP6718376B2 (ja) * 2014-02-07 2020-07-08 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用

Similar Documents

Publication Publication Date Title
JP2017514850A5 (enExample)
AU2018256605C1 (en) Benzoquinone Derivative E3330 in Combination with Chemotherapeutic Agents for the Treatment of Cancer and Angiogenesis
JP6635945B2 (ja) 多動性運動障害を処置するためのｖｍａｔ２インヒビター
JP7221922B2 (ja) 組み合せ抗細菌組成物および短期抗細菌レジメン
RU2013113222A (ru) Способы лечения или профилактики тромбообразования или эмболии
JP2016540738A5 (enExample)
BR112015015477A2 (pt) derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk
RU2014102362A (ru) Антитромботические соединения
WO2011113802A3 (en) Imidazopyridine and purine compounds, compositions and methods of use
FI3426285T3 (fi) Pegyloidun urikaasin formulaatioita ja annoksia
WO2016210003A3 (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
JP2013508289A5 (enExample)
JP2017513809A5 (enExample)
JP2015509539A5 (enExample)
MX418886B (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo
TN2022000092A1 (en) Oral complement factor d inhibitors
FI3706724T3 (fi) Suun kautta otettavia rifamysiini sv -koostumuksia
TN2022000095A1 (en) Oral complement factor d inhibitors
JP2016515550A5 (enExample)
JP2015504094A5 (enExample)
JP2016512247A5 (enExample)
RU2019109695A (ru) Лекарственная форма для пролонгированного ослабления симптомов
JP2019516726A5 (enExample)
RU2018104691A (ru) Композиции с модифицированным высвобождением ницерголина
JP2013544795A5 (enExample)